{"protocolSection": {"identificationModule": {"nctId": "NCT01766778", "orgStudyIdInfo": {"id": "CLAF237AHK01"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin", "officialTitle": "A Local Phase IV, Multicenter, Open-label Study to Evaluate Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-05-13", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2015-10-22", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-10-22", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-01-09", "studyFirstSubmitQcDate": "2013-01-09", "studyFirstPostDateStruct": {"date": "2013-01-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-02-23", "resultsFirstSubmitQcDate": "2017-02-23", "resultsFirstPostDateStruct": {"date": "2017-04-10", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-04-07", "lastUpdatePostDateStruct": {"date": "2017-05-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study was to observe change of HbA1c over time from baseline to month 12. The ultimate goal of this study was to provide a local reference value to the physicians \\& patients in the future when they consider initiating Vildagliptin and taking balance between efficacy, compliance, risk factors, convenience and medication cost."}, "conditionsModule": {"conditions": ["Type-2 Diabetes Mellitus"], "keywords": ["type-2 diabetes mellitus, inadequately controlled Metformin"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 117, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LAF237 (vildagliptin) 50mg once daily (QD)", "type": "ACTIVE_COMPARATOR", "description": "Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin", "interventionNames": ["Drug: LAF237 (vildagliptin)", "Drug: Metformin"]}, {"label": "LAF237 (vildagliptin) 50mg twice daily (BID)", "type": "ACTIVE_COMPARATOR", "description": "Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin", "interventionNames": ["Drug: LAF237 (vildagliptin)", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "LAF237 (vildagliptin)", "description": "Vildagliptin 50mg capsule", "armGroupLabels": ["LAF237 (vildagliptin) 50mg once daily (QD)", "LAF237 (vildagliptin) 50mg twice daily (BID)"], "otherNames": ["LAF237"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin maximum tolerance dose", "armGroupLabels": ["LAF237 (vildagliptin) 50mg once daily (QD)", "LAF237 (vildagliptin) 50mg twice daily (BID)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 12", "description": "HbA1c is an integrated measure of average glucose concentration in plasma in the last 2-3 months. Blood samples were collected to analyze HbA1c", "timeFrame": "Baseline, Month 12 (weeK 52)"}], "secondaryOutcomes": [{"measure": "Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 3, 6, 9 and 12 (Based on MMRM Analysis)", "description": "HbA1c is an integrated measure of average glucose concentration in plasma in the last 2-3 months. Blood samples were collected to analyze HbA1c. Mixed Model of Repeated Measures (MMRM) was used to analyze this outcome. For the MMRM analysis, the model includes terms for treatment, period, treatment-by-period interaction and baseline value, and further adjusted by age, pre-existing hypertension and microvascular and macrovascular complications for diabetes mellitus. The variables selected for baseline adjustment were based on the lowest AIC.", "timeFrame": "Baseline, Month 3, 6, 9 and 12"}, {"measure": "Change in Fasting Plasma Glucose (FPG) From Baseline to Month 3, 6, 9 and 12 (Based on MMRM Analysis)", "description": "Blood samples were collected to analyze fasting plasma glucose. Mixed Model of Repeated Measures (MMRM) was used to analyze this outcome. For the MMRM analysis, the model included terms for treatment, period, treatment-by-period interaction and baseline value, and further adjusted by pre-existing hypertension. The variable selected for baseline adjustment was based on the lowest AIC.", "timeFrame": "Baseline, Month 3, 6, 9 and 12"}, {"measure": "Percentage of Patients Achieving Good Glycemic Control", "description": "Blood samples were collected to analyze HbA1c. Good glycemic control is defined as patient achieving Hb1Ac \\< 7.0%. Percentage of patients who achieved HbA1c less than 7.0% at month 3, 6, 9 and 12 were reported for this endpoint.", "timeFrame": "Month 3, 6, 9, 12"}, {"measure": "Percentage of Overall Drug Compliance in 12 Months", "description": "The overall drug compliance (%) = (Observed Consumption / Expected Consumption) x 100% Where (Observed Consumption / Expected Consumption) = \\[1- (Number of missing tablets from all visits/(sum of Allocated Daily Dosage (in tablets) from all visits \u00d7 No. of Days between the Date Dispensed and the Date Returned))\\]", "timeFrame": "Month 12"}, {"measure": "Number of Patients With Adverse Events, Serious Adverse Events and Death as an Assessment of Overall Safety and Tolerability", "description": "This analysis reported percentage patients with adverse events and patient discontinued from the study due to adverse events. Aslo, percentage of patients with serious adverse events and death was reported.", "timeFrame": "Month 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or Female in age \u226518 at Visit 1\n2. Type 2 diabetes mellitus (T2DM) patients on their maximum tolerated dose of Metformin for more than 3 months\n3. HbA1c (glycosylated hemoglobin) at Visit 1 greater than 7.0%\n4. With nearest documented record of HbA1c before Visit 1 greater than 7.0% after patient reached his/her maximum tolerated dose of Metformin\n\nKey Exclusion Criteria:\n\n1. Patients with hepatic impairment, including patients with a pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2.5 X the upper limit of normal at Visit 1\n2. Patients with moderate or severe renal impairment or end-stage-renal-disease (ESRD) on haemodialysis at the time of enrolment\n3. Patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption\n4. Pregnant women or breastfeeding women at the time of enrolment\n5. Use of insulin or other oral anti-diabetic drug (OAD) apart from Metformin in the past for T2DM treatment", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Hong Kong SAR", "country": "Hong Kong"}, {"facility": "Novartis Investigative Site", "city": "HongKong", "country": "Hong Kong", "geoPoint": {"lat": 22.27832, "lon": 114.17469}}, {"facility": "Novartis Investigative Site", "city": "Tuen Mun", "country": "Hong Kong", "geoPoint": {"lat": 22.39175, "lon": 113.97157}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "There was 117 patients randomized and received either Vildagliptin 50mg QD or 50 mg BID.", "groups": [{"id": "FG000", "title": "LAF237 (Vildagliptin) 50mg Once Daily (QD)", "description": "Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin"}, {"id": "FG001", "title": "LAF237 (Vildagliptin) 50mg Twice Daily (BID)", "description": "Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Intent to treat population", "numSubjects": "56"}, {"groupId": "FG001", "numSubjects": "61"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "51"}, {"groupId": "FG001", "numSubjects": "57"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Intent to treat (ITT) included all randomized patients who received at least one dose of study medication.", "groups": [{"id": "BG000", "title": "LAF237 (Vildagliptin) 50mg Once Daily (QD)", "description": "Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin"}, {"id": "BG001", "title": "LAF237 (Vildagliptin) 50mg Twice Daily (BID)", "description": "Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "56"}, {"groupId": "BG001", "value": "61"}, {"groupId": "BG002", "value": "117"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58", "spread": "10.3"}, {"groupId": "BG001", "value": "59", "spread": "10.0"}, {"groupId": "BG002", "value": "58", "spread": "10.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "57"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "60"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 12", "description": "HbA1c is an integrated measure of average glucose concentration in plasma in the last 2-3 months. Blood samples were collected to analyze HbA1c", "populationDescription": "Intent to treat (ITT) analysis set included all randomized patients who received at least one dose of study medication. Patients with both baseline and 12 month data were included in this analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline, Month 12 (weeK 52)", "groups": [{"id": "OG000", "title": "LAF237 (Vildagliptin) 50mg Once Daily (QD)", "description": "Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin"}, {"id": "OG001", "title": "LAF237 (Vildagliptin) 50mg Twice Daily (BID)", "description": "Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "1.01"}, {"groupId": "OG001", "value": "-1.0", "spread": "1.24"}]}]}]}, {"type": "SECONDARY", "title": "Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 3, 6, 9 and 12 (Based on MMRM Analysis)", "description": "HbA1c is an integrated measure of average glucose concentration in plasma in the last 2-3 months. Blood samples were collected to analyze HbA1c. Mixed Model of Repeated Measures (MMRM) was used to analyze this outcome. For the MMRM analysis, the model includes terms for treatment, period, treatment-by-period interaction and baseline value, and further adjusted by age, pre-existing hypertension and microvascular and macrovascular complications for diabetes mellitus. The variables selected for baseline adjustment were based on the lowest AIC.", "populationDescription": "Intent to treat (ITT) analysis set included all randomized patients who received at least one dose of study medication. .", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline, Month 3, 6, 9 and 12", "groups": [{"id": "OG000", "title": "LAF237 (Vildagliptin) 50mg Once Daily (QD)", "description": "Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin"}, {"id": "OG001", "title": "LAF237 (Vildagliptin) 50mg Twice Daily (BID)", "description": "Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "61"}]}], "classes": [{"title": "3 month from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "0.11"}, {"groupId": "OG001", "value": "-0.9", "spread": "0.10"}]}]}, {"title": "6 month from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "0.13"}, {"groupId": "OG001", "value": "-0.9", "spread": "0.12"}]}]}, {"title": "9 month from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "0.13"}, {"groupId": "OG001", "value": "-0.7", "spread": "0.13"}]}]}, {"title": "12 month from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "0.15"}, {"groupId": "OG001", "value": "-0.6", "spread": "0.15"}]}]}]}, {"type": "SECONDARY", "title": "Change in Fasting Plasma Glucose (FPG) From Baseline to Month 3, 6, 9 and 12 (Based on MMRM Analysis)", "description": "Blood samples were collected to analyze fasting plasma glucose. Mixed Model of Repeated Measures (MMRM) was used to analyze this outcome. For the MMRM analysis, the model included terms for treatment, period, treatment-by-period interaction and baseline value, and further adjusted by pre-existing hypertension. The variable selected for baseline adjustment was based on the lowest AIC.", "populationDescription": "Intent to treat (ITT) analysis set included all randomized patients who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Month 3, 6, 9 and 12", "groups": [{"id": "OG000", "title": "LAF237 (Vildagliptin) 50mg Once Daily (QD)", "description": "Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin"}, {"id": "OG001", "title": "LAF237 (Vildagliptin) 50mg Twice Daily (BID)", "description": "Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "61"}]}], "classes": [{"title": "3 month from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "0.18"}, {"groupId": "OG001", "value": "-1.3", "spread": "0.16"}]}]}, {"title": "6 month from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "0.18"}, {"groupId": "OG001", "value": "-0.9", "spread": "0.17"}]}]}, {"title": "9 month from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "0.17"}, {"groupId": "OG001", "value": "-1.0", "spread": "0.16"}]}]}, {"title": "12 month from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "0.20"}, {"groupId": "OG001", "value": "-0.8", "spread": "0.20"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving Good Glycemic Control", "description": "Blood samples were collected to analyze HbA1c. Good glycemic control is defined as patient achieving Hb1Ac \\< 7.0%. Percentage of patients who achieved HbA1c less than 7.0% at month 3, 6, 9 and 12 were reported for this endpoint.", "populationDescription": "Intent to treat (ITT) analysis set included all randomized patients who received at least one dose of study medication. 'n' indicates patients with HbA1c data in that time point.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Month 3, 6, 9, 12", "groups": [{"id": "OG000", "title": "LAF237 (Vildagliptin) 50mg Once Daily (QD)", "description": "Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin"}, {"id": "OG001", "title": "LAF237 (Vildagliptin) 50mg Twice Daily (BID)", "description": "Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "61"}]}], "classes": [{"title": "At Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "33.3"}, {"groupId": "OG001", "value": "47.5"}]}]}, {"title": "At Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "39.2"}, {"groupId": "OG001", "value": "45.6"}]}]}, {"title": "At Month 9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "45.1"}, {"groupId": "OG001", "value": "47.4"}]}]}, {"title": "At Month 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "50"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "49.0"}, {"groupId": "OG001", "value": "40.0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Overall Drug Compliance in 12 Months", "description": "The overall drug compliance (%) = (Observed Consumption / Expected Consumption) x 100% Where (Observed Consumption / Expected Consumption) = \\[1- (Number of missing tablets from all visits/(sum of Allocated Daily Dosage (in tablets) from all visits \u00d7 No. of Days between the Date Dispensed and the Date Returned))\\]", "populationDescription": "Intent to treat (ITT) analysis set included all randomized patients who received at least one dose of study medication. Patients who had reported dosing compliance were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of overall drug compliance", "timeFrame": "Month 12", "groups": [{"id": "OG000", "title": "LAF237 (Vildagliptin) 50mg Once Daily (QD)", "description": "Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin"}, {"id": "OG001", "title": "LAF237 (Vildagliptin) 50mg Twice Daily (BID)", "description": "Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "96.90", "spread": "5.682"}, {"groupId": "OG001", "value": "97.48", "spread": "6.277"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Adverse Events, Serious Adverse Events and Death as an Assessment of Overall Safety and Tolerability", "description": "This analysis reported percentage patients with adverse events and patient discontinued from the study due to adverse events. Aslo, percentage of patients with serious adverse events and death was reported.", "populationDescription": "Intent to treat (ITT) analysis set included all randomized patients who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Patients", "timeFrame": "Month 12", "groups": [{"id": "OG000", "title": "LAF237 (Vildagliptin) 50mg Once Daily (QD)", "description": "Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin"}, {"id": "OG001", "title": "LAF237 (Vildagliptin) 50mg Twice Daily (BID)", "description": "Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "61"}]}], "classes": [{"title": "Any adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "14"}]}]}, {"title": "Serious adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Patients discontinued due to any AE/SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "eventGroups": [{"id": "EG000", "title": "LAF237 (Vildagliptin) 50mg Once Daily (QD)", "description": "Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin", "seriousNumAffected": 2, "seriousNumAtRisk": 56, "otherNumAffected": 14, "otherNumAtRisk": 56}, {"id": "EG001", "title": "LAF237 (Vildagliptin) 50mg Twice Daily (BID)", "description": "Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin", "seriousNumAffected": 2, "seriousNumAtRisk": 61, "otherNumAffected": 7, "otherNumAtRisk": 61}], "seriousEvents": [{"term": "Duodenitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 61}]}, {"term": "Leukemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 61}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 61}]}, {"term": "stone impairation over proximal urethra", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 61}]}], "otherEvents": [{"term": "Tinea", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 61}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 56}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 61}]}, {"term": "Elevated liver function test", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 56}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 61}]}, {"term": "Hyperkalemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 61}]}, {"term": "Hypokalemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 56}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 61}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 56}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 61}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 56}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 61}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 56}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 61}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "trialandresults.registries@novartis.com", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077597", "term": "Vildagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1857", "name": "Vildagliptin", "asFound": "Factor Xa", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}